EDX Medical announced a new partnership, securing exclusive rights to distribute mirdetect GmbH’s M371 diagnostic test for testicular cancer. This Cambridge-based company is known for its innovative digital diagnostic tools, which target critical health issues, including cancer, cardiovascular, and infectious diseases.
The M371 test is a blood-based diagnostic tool that identifies key biomarkers associated with early-stage testicular cancer, particularly relevant to younger male populations who are most affected by this cancer type. Under this agreement, mirdetect will make the test available in the UK, Sweden, Finland, Norway, and Denmark, expanding its reach in these regions.
Chief Executive Officer Mike Hudson expressed enthusiasm over the partnership, highlighting its alignment with EDX Medical’s range of diagnostic solutions. Hudson noted that the collaboration with mirdetect positions the company to help healthcare professionals deliver more personalised treatment decisions. He added that EDX Medical intends to deepen its work with mirdetect, with plans to enhance and develop the M371 test further.
This agreement strengthens EDX Medical’s diagnostic offerings and marks a step forward in the early detection and treatment of testicular cancer across key European markets.
EDX Medical Group Plc (AQSE:EDX) is a global specialist in digital clinical diagnostics; developing and supporting high-performance products and services to provide cost-effective prediction of disease risk, inform clinical decision-making, enable personalised healthcare and accelerate the development of new medicines for cancer, neurology, heart disease and infectious diseases.
